We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+73.06%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$912M
AUM Growth
-$156M
Cap. Flow
-$257M
Cap. Flow %
-28.19%
Top 10 Hldgs %
35.78%
Holding
190
New
54
Increased
34
Reduced
35
Closed
53

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.96M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.6M
4
JBIO
Jade Biosciences
JBIO
+$8.03M
5
PYXS icon
Pyxis Oncology
PYXS
+$6.99M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$26.5M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$21.4M
3
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$19.1M
4
NUVL
Nuvalent
NUVL
+$12.5M
5
IRON icon
Disc Medicine
IRON
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLRN
176
CALL
DELISTED
ACELYRIN
SLRN
– –
-336,900
Closed -$2.51M
SRPT icon
177
PUT
Sarepta Therapeutics
SRPT
$1.57B
– –
-101,800
Closed -$9.82M
VERV
178
PUT
DELISTED
Verve Therapeutics
VERV
– –
-41,300
Closed -$576K
XENE icon
179
PUT
Xenon Pharmaceuticals
XENE
$6.06B
– –
-154,089
Closed -$7.1M
XHB icon
180
State Street SPDR S&P Homebuilders ETF
XHB
$1.6B
– –
-200,000
Closed -$19.1M
OKUR
181
CALL
OnKure Therapeutics
OKUR
$154M
– –
-108,260
Closed -$1.73M
OKUR
182
OnKure Therapeutics
OKUR
$154M
– –
-42,130
Closed -$674K
OKUR
183
PUT
OnKure Therapeutics
OKUR
$154M
– –
-43,260
Closed -$692K
MOR
184
CALL
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-400,000
Closed -$3.96M
TCON
185
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
-138,277
Closed -$484K
FUSN
186
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-500,000
Closed -$4.81M
KRTX
187
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-58,600
Closed -$18.5M
ICVX
188
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-440,000
Closed -$6.93M
IMGN
189
CALL
DELISTED
Immunogen Inc
IMGN
– –
-456,800
Closed -$13.5M
IMGN
190
DELISTED
Immunogen Inc
IMGN
– –
-90,162
Closed -$2.67M
4 5 6 7
8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ikarian Capital held 190 positions worth $912M, down 15% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Ikarian Capital withdrew a net $257M in Q1 2024, closing 53 positions and reducing 35 holdings. Its most notable exit was argenx, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 32% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Alnylam Pharmaceuticals worth $7.7M.

  • Ikarian Capital's largest Q1 2024 buy was Alnylam Pharmaceuticals: 51,541 shares worth $7.7M.
  • Ikarian Capital added most to Corbus Pharmaceuticals in Q1 2024, an estimated $8.96M increase.
  • Ikarian Capital's biggest Q1 2024 reduction was Longboard Pharmaceuticals, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited argenx in Q1 2024, selling an estimated $26.5M.
  • Ikarian Capital's ten largest holdings make up 36% of its $912M portfolio in Q1 2024.
  • Ikarian Capital opened 54 new positions and closed 53 in Q1 2024.
  • Ikarian Capital's portfolio value fell 15% quarter-over-quarter to $912M.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.